HLF and cancer: Integrating these data and the observed downregulation of the HLF gene in the majority of human cancer in our research, we can suggest that cancer patients with lower expression of the HLF gene possibly are resistant to Paclitaxel, Dasatinib, Docetaxel, AZ628, Z-LLNle-CHO, WH-4-023, Bortezomib, Bleomycin (50 μM), 17-AAG, MLN4924, Vinblastine, YM155, Vinorelbine, CI-1040, BEZ235, Trametinib, RDEA119, selumetinib, and PD-0325901 and sensitive to CAL-101 and Navitoclax.